Estrategias Combinadas en Inmunoterapia Traslacional
ITC
University of California, San Francisco
San Francisco, Estados UnidosPublikationen in Zusammenarbeit mit Forschern von University of California, San Francisco (8)
2021
-
DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type i conventional dendritic cells
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 5
-
Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
Journal of Thoracic Oncology
2020
-
Long-term outcomes and retreatment among patients with previously treated, programmed death-ligand 1‒positive, advanced non‒small-cell lung cancer in the KEYNOTE-010 study
Journal of Clinical Oncology, Vol. 38, Núm. 14, pp. 1580-1591
2019
-
TGFb blockade enhances radiotherapy abscopal efficacy effects in combination with anti-PD1 and anti-CD137 immunostimulatory monoclonal antibodies
Molecular Cancer Therapeutics, Vol. 18, Núm. 3, pp. 621-631
2017
-
Predictors of responses to immune checkpoint blockade in advanced melanoma
Nature Communications, Vol. 8, Núm. 1
2016
-
Immunodynamics: A cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Journal for ImmunoTherapy of Cancer, Vol. 4, Núm. 1
2014
-
Classification of current anticancer immunotherapies
Oncotarget, Vol. 5, Núm. 24, pp. 12472-12508
2011
-
Defining the critical hurdles in cancer immunotherapy
Journal of Translational Medicine